Short answer
Maze Therapeutics, Inc. (MAZE) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 with net income of −$45M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- −100.0% QoQ
- Net income
- −$45M
- −32.8% YoY · −84.8% QoQ
- EPS (diluted)
- −$0.77
- −13.2% YoY · −71.1% QoQ
Source: XBRL data from the Maze Therapeutics, Inc. (MAZE) Q2 2026 10-Q on SEC EDGAR. USD.
Maze Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New debt risk triggered by February 2026 Hercules Loan Agreement: $40.0 million funded, secured by substantially all assets except intellectual property
- Liquidity risk: $494.9 million cash, equivalents, and marketable securities projected to fund operations for at least one year
- Regulatory risk: FDA-required additional studies or trial delays could materially increase expenses and defer profitability
- Clinical-development risk: MZE829 and MZE782 remain in early clinical development without demonstrated efficacy or commercial revenue
- Dilution risk: April 2026 offering issued 5,540,000 shares and 850,000 pre-funded warrants for approximately $144.6 million net proceeds
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Maze Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.